Sales rose 11%, while Repligen reported a $38 million net loss.

Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY, and a net loss of $38M. The company completed the BioLife acquisition, raising FY26 revenue guidance to $844M-$852M. Adjusted EPS was $0.53. CEO Olivier Loeillot highlighted strong performance and integration progress. (RGEN)

Original reporting
Published Oct 27, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RGEN
Bullish
high confidence
Mentioned
$RGEN
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The raised revenue guidance reflects expected contributions from the BioLife deal, suggesting stronger future cash flow.

02

Market read

First‑report earnings and guidance raise for Repligen, a material event for biotech investors.

03

What to watch

Potential foreign‑currency headwinds and execution risk of the BioLife integration may temper upside.

Relevance 8/10Novelty 8/10Timing: after release today

Background

Repligen, a bioprocessing company, announced its Q3 results and updated FY2026 guidance after completing the BioLife acquisition.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 2026 revenue of $209.3M (+11% YoY) and raised full-year 2026 revenue guidance to $844‑$852M.

Expected impact

potential upward pressure as market prices in higher revenue outlook

Evidence & confidence

Revenue growth and raised guidance outweigh the reported quarterly loss, indicating improved future earnings.

Market effects

Highlights growth in bioprocessing and cell‑therapy consumables, benefiting peers in biotech manufacturing.

US biotech stocks may see modest gains following the upbeat guidance.

Signals expanding demand for cell‑therapy platforms worldwide.

Counterpoint

The quarterly GAAP loss and integration costs could pressure the stock if synergies lag.

Key entities

  • Repligen Corporation

    US‑listed bioprocessing firm (NASDAQ:RGEN) reporting earnings and guidance.

  • BioLife Solutions

    Acquired firm adding cell‑therapy consumables platform.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.